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Background: The aim of the current study was to estimate sex- and age-specific incidence rates of chronic fatigue
syndrome/myalgic encephalomyelitis (CFS/ME) using population-based registry data. CFS/ME is a debilitating
condition with large impact on patients and their families. The etiology is unknown, and the distribution of the
disease in the general population has not been well described.
Methods: Cases of CFS/ME were identified in the Norwegian Patient Register (NPR) for the years 2008 to 2012.
The NPR is nationwide and contains diagnoses assigned by specialist health care services (hospitals and outpatient
clinics). We estimated sex- and age-specific incidence rates by dividing the number of new cases of CFS/ME in each
category by the number of person years at risk. Incidence rate ratios were estimated by Poisson regression with sex,
age categories, and year of diagnosis as covariates.
Results: A total of 5,809 patients were registered with CFS/ME during 2008 to 2012. The overall incidence rate was
25.8 per 100,000 person years (95% confidence interval (CI): 25.2 to 26.5). The female to male incidence rate ratio of
CFS/ME was 3.2 (95% CI: 3.0 to 3.4). The incidence rate varied strongly with age for both sexes, with a first peak in
the age group 10 to 19 years and a second peak in the age group 30 to 39 years.
Conclusions: Early etiological clues can sometimes be gained from examination of disease patterns. The strong
female preponderance and the two age peaks suggest that sex- and age-specific factors may modulate the risk
of CFS/ME.
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Chronic fatigue syndrome (CFS), or myalgic encephalo-
myelitis (ME), is a debilitating, medically unexplained
condition [1]. The terms CFS and ME are often used
interchangeably, and Norwegian health authorities rec-
ommend using the combined term CFS/ME [2].
CFS/ME is an unspecific condition for which it has
been difficult to establish objective medical criteria, and
the CFS/ME diagnosis has been debated in the medical* Correspondence: inger.johanne.bakken@fhi.no
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unless otherwise stated.community for many years [3]. Symptoms may fluctuate
and vary in intensity within and among patients, but
persistent or relapsing fatigue is always present [4]. Func-
tional status and wellbeing are often strongly affected [5].
While the etiology of CFS/ME remains largely un-
known, several trigger mechanisms have been proposed,
including infections, stress and trauma [1]. A sudden in-
crease in CFS/ME was reported following a large water-
borne outbreak of giardiasis in Bergen, Norway, in 2004
[6]. Autoimmune etiology has also been suggested, based
on the observation that B-lymphocyte depletion with the
monoclonal anti-CD20 antibody rituximab was associatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with CFS/ME [7].
Due to terminological variations and diagnostic in-
consistencies, it is difficult to assess the prevalence and
incidence rate of CFS/ME in a population. Overall pre-
valence estimates vary from 0.1% to 2.5%, depending on
the criteria applied [1,8].
The aim of the current study was to estimate sex- and
age-specific incidence rates of CFS/ME in Norway dur-
ing a five-year period, using data from a nationwide
registry containing diagnoses assigned by Norwegian
specialist health care services (hospitals and outpatient
clinics).
Methods
The use of national data and data linkage procedures
were approved by the Regional Committee for Medical
and Health Research Ethics, South-East Norway. The
ethical approval permitted the use of national level data.
The research group did not at any time point have
access to names or personal identification numbers, and
all data storage and handling have been carried out within
strict standards to ensure data privacy and protection.
The study population was the complete Norwegian
population five years old and older as of 1 January 2008,
registered in the Central Population Registry. For each
individual we had access to information on vital status
(dates for emigration or death) for the entire study
period, 2008 to 2012. All individuals were assigned a
study allocation number based on the 11-digit personal
identification number unique to all Norwegian citizens
and migrants with legal residence in Norway.
Information on CFS/ME was obtained from the
Norwegian Patient Register (NPR), which is a data-
base containing data from all Norwegian hospitals and
outpatient clinics. For each hospitalization or outpatient
visit, reporting of data to the NPR is mandatory and is
linked to the reimbursement system. Discharge diagno-
ses are reported as International Classification of Disease,
version 10 (ICD-10) codes. Personal identification num-
bers have been reported to the NPR from 2008 onwards,
making tracking of subjects possible for research pur-
poses. Reporting of the personal identification number has
been nearly complete from the start [9]. The personal
identification number is stored in encrypted form in
the NPR.
Cases of CFS/ME were all in- and outpatients in
Norwegian hospitals who were registered with the ICD-10
code G93.3 (‘postviral fatigue syndrome/benign myalgic
encephalomyelitis’). Data from mental health care fa-
cilities were not included. In addition to the ICD-code,
the NPR provided information about sex, year of birth,
dates for hospitalizations and outpatient visits, and
a study allocation number for data linkage. The firstregistered G93.3 episode for each patient was used
in the analyses.
Age was calculated as the age in 2008 by subtracting
year of birth from calendar year. We estimated sex- and
age-specific incidence rates by dividing the number of
new cases of CFS/ME in each sex/age category by the
total number of person years at risk in the same cat-
egory. Time at risk for each individual was calculated by
using the information on vital status. Age was catego-
rized in five-year intervals (5 to 9, 10 to 14, …, 55+). We
estimated the incidence rate ratio of CFS/ME by apply-
ing Poisson regression with sex, age categories, and year
of diagnosis as covariates and compared estimated inci-
dence rates in sex and age categories.
The Stata software package, Version 11.2 (StataCorp.
2009. Stata Statistical Software: Release 11. College Station,
TX, USA: StataCorp LP) was used for data analysis.
Results
During the years 2008 to 2012, 5,809 patients (75.4%
women) five years old or older in 2008 were registered
with CFS/ME. Figure 1 shows the number of cases in
one-year age intervals for women and men separately.
For both sexes, two distinct peaks in the number of cases
were observed, the first in the age group 10 to 19 years
and the second in the age group 30 to 39 years.
Table 1 shows the incidence rate of CFS/ME by year,
sex and age category. The incidence rate was fairly stable
over the years of follow-up. The overall incidence rate
per 100,000 person years was 39.4 (95% confidence in-
terval (CI): 38.2 to 40.6) for women, while the corre-
sponding figure was 12.9 (95% CI: 12.3 to 13.6) for men.
This gives an incidence rate ratio of 3.2 (95% CI: 3.0 to
3.4) for women compared to men. The incidence rate
was highest in the age groups 10 to 14, 15 to 19, 30 to
34 and 35 to 39 years.
Figure 2 shows the number of cases per year by age
category for men and women separately, estimated from
the Poisson regression model. The non-overlapping CIs
support the existence of two age peaks in the distribu-
tion indicated by the raw data (Figure 1).
Figure 3 shows the estimated incidence rate per 100,000
person years for men and women separately. After ad-
justment for population figures, the pattern with two age
peaks is clear for women, whereas a second peak is not
evident for men.
Repeating the analyses including a ‘wash-out’ period of
two years (that is, excluding data for all patients first
registered in 2008 and 2009) gave similar sex and age
patterns as those described here (results not shown).
Norway is divided into four health regions, with most
people living in the South-East region. Although some
variations were observed, the pattern with a strong pre-
ponderance of women and higher risk of CFS/ME in the
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Figure 1 Observed number of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) cases by sex and one-year age groups
(age in 2008). Data from the Norwegian Patient Register 2008 to 2012.
Table 1 Incidence rates and incidence rate ratios of CFS/ME in the Norwegian population according to year, sex and
age in 2008 (categorized), 2008 to 2012
Variable Number of cases Number of person years Incidence rate per 100,000
person years (95% CI)
Incidence rate ratio (95% CI)
Year
2008 1,172 4,494,062 26.1 (24.6 to 27.6) 1.0 (ref.)
2009 1,113 4,491,822 24.8 (23.3 to 26.3) 0.9 (0.9 to 1.0)
2010 1,104 4,449,683 24.8 (23.4 to 26.3) 0.9 (0.9 to 1.0)
2011 1,222 4,395,325 27.8 (26.3 to 29.4) 1.0 (1.0 to 1.1)
2012 1,198 4,342,818 27.6 (26.1 to 29.2) 0.9 (0.9 to 1.1)
Sex
Male 1,430 11,050,966 12.9 (12.3 to 13.6) 1.0 (ref.)
Female 4,379 11,122,744 39.4 (38.2 to 40.6) 3.2 (3.0 to 3.4)
Age category (years)
5 to 9 121 1,497,289 8.1 (6.7 to 9.7) 1.3 (1.1 to 1.6)
10 to 14 690 1,578,106 43.7 (40.5 to 47.1) 7.1 (6.3 to 8.1)
15 to 19 689 1,598,802 43.1 (39.9 to 46.4) 7.0 (6.2 to 8.0)
20 to 24 473 1,481,322 31.9 (29.1 to 34.9) 5.2 (4.5 to 5.9)
25 to 29 492 1,523,923 32.3 (29.5 to 35.3) 5.2 (4.6 to 6.0)
30 to 34 688 1,603,520 42.9 (39.6 to 46.2) 7.0 (6.1 to 7.9)
35 to 39 771 1,809,970 42.6 (39.6 to 45.7) 6.9 (6.1 to 7.8)
40 to 44 614 1,797,270 34.2 (31.5 to 37.0) 5.6 (4.9 to 6.3)
45 to 49 496 1,636,483 30.3 (27.7 to 33.1) 4.9 (4.3 to 5.6)
50 to 54 383 1,564,478 24.5 (22.1 to 27.1) 4.0 (3.4 to 4.6)
55+ 392 6,082,547 6.2 (5.6 to 6.9) 1.0 (ref.)
CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; CI, confidence interval.
Bakken et al. BMC Medicine 2014, 12:167 Page 3 of 7
http://www.biomedcentral.com/1741-7015/12/167
050
100
150
E
st
im
at
ed
 N
um
be
r 
of
 Y
ea
rly
 C
as
es
 (
N
)
5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55+
Age Categories (years)
Women
Men
Figure 2 Number of yearly cases of CFS/ME by sex and five-year age groups estimated by Poisson regression analyses. CFS/ME, chronic
fatigue syndrome/myalgic encephalomyelitis.
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persisted when performing the analyses for each health
region separately (results not shown).
Discussion
This is the largest study to date of CFS/ME, including
5,809 patients and using national population-based re-
gistry data. To our knowledge, this is also the first study
to investigate the distribution of CFS/ME by sex and age
in a population. The main new finding is the distinct age
peaks in the incidence of CFS/ME, with a first peak in
the number of cases in the age group 10 to 19 years and
a second peak in the age group 30 to 39 years. Although
a higher prevalence in women than in men has been a0
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Figure 3 Estimated incidence rates of CFS/ME per 100,000 person yea
syndrome/myalgic encephalomyelitis.consistent finding in previous studies [1], most epide-
miological studies so far have been too small to report
age distributions [10-15] or have only reported the age
distribution for women and men combined [16,17].
The strength of the current study is the access to
individual-level hospital data from an entire country, which
could be linked to high-quality population data by means
of personal identification numbers. In Norway, access to
specialist health care services requires referral from a
general practitioner, and the cases included in the NPR
probably represent the more severe and established cases
of CFS/ME. The Norwegian health care system is financed
through governmental funding. All hospitalizations are
free of charge, while outpatients 16 years old or older are0-34 35-39 40-44 45-49 50-54 55+
ories (years)
Women
Men
rs by sex and five-year age groups. CFS/ME, chronic fatigue
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little influence on patterns of seeking health care.
It is reasonable to assume that the more severe cases
of CFS/ME are referred to specialist health care services,
and that this is also the case for young patients and
people with sudden onset of symptoms. Even so, the
estimated incidence rates in the current study may differ
from the true population incidence. Since our study is
based on diagnoses reported from specialist health care
services, we have calculated the incidence of being diag-
nosed with the condition and not the incidence of the
condition as such. Also, some patients regarded as inci-
dent cases in the current study may have been diagnosed
the first time before the start of follow-up. Such cases
will contribute to an overestimation of the true inci-
dence rate. On the other hand, patients with less severe
CFS/ME are probably in many cases only diagnosed in
the primary health care system, a mechanism that leads
to underestimation of the incidence rate. However, it
seems unlikely that such factors have severely biased the
incidence rate ratio of women versus men or the inci-
dence rate ratios of the different age categories seen in
our study.
The main weakness of this study is the possible vari-
ation in the use of ICD-10 code G93.3 for CFS/ME due
to the inherent heterogeneity of the disease. We did not
have access to information from medical records and
could not investigate the diagnostic criteria applied in
individual patients. According to the recommendations
from the Norwegian Directorate of Health, children with
suspected CFS/ME should have the diagnosis confirmed
by a pediatrician [2]. Thus, children receiving the diag-
nosis of CFS/ME are routinely referred to their local
hospital for the diagnostic work-up. Complicated cases
may be further referred to regional university hospitals.
After the diagnosis of CFS/ME is made, patients are typ-
ically followed up in primary care. Adults may receive a
diagnosis of CFS/ME after evaluation by a general prac-
titioner. However, since the diagnosis requires that other
possible diagnoses are ruled out, most patients have
most likely also been seen by a specialist at a local hos-
pital during the diagnostic work-up. Patients may also
be referred to one of the four university hospitals which
have specialized units for diagnosing CFS/ME or to
the national CFS/ME-center at Oslo University Hospital.
Follow-up after diagnosis is the responsibility of general
practitioners.
The Norwegian Directorate of Health has stated that
ICD-10 code G93.3 is to be used for this disorder [2].
However, cases in the present study come from a large
number of different hospitals and the criteria used to
diagnose CFS/ME might have varied. In a recent study,
most Norwegian hospitals reported that they had used
either the Canadian 2003 criteria [18] or the CDC 1994criteria [4] when diagnosing CFS/ME in adults [19].
Pediatricians generally reported they follow the guidelines
of the Norwegian Pediatric Association [20], which for-
mally refer to the CDC 1994 criteria, but also recommend
using a practical, clinical definition of CFS/ME in children
with otherwise unexplained severe fatigue of more than
three months duration. We cannot exclude the possibility
that the relatively high incidence in children and adoles-
cents may be partly due to the use of a less strict case def-
inition of CFS/ME in young people. However, we find
it unlikely that this potential over-reporting is substan-
tial, as pediatricians probably are restrictive in using this
diagnosis.
Some patients fulfilling the criteria for a diagnosis of
CFS/ME may be missed in the current study due to the
possible use of ICD-10 codes for other conditions with
overlapping symptoms, such as neurasthenia, burn-out
syndrome, malaise and fatigue, or fibromyalgia. However,
while a diagnosis of G93.3 gives the right to social security
benefits, such as sickness benefit or disability pension, this
is most often not the case for, for example, neurasthenia,
which includes many of the same symptoms but to a
milder degree [2]. According to the guide from the
Norwegian Directorate of Health, the code for neurasthe-
nia should only be used when CFS/ME has been ruled out
[2]. The ICD-10 guidelines also state that F48.0 (‘neuras-
thenia’) excludes G93.3 [21]. Thus, we regard G93.3 as the
ICD-10 code most closely related to CFS/ME.
The incidence rates reported here are somewhat higher
than the rates reported from the UK for the time period
1990 to 2001 [16], while the female to male ratios are
comparable. Although the prognosis for an improvement
in symptoms of CFS/ME is fairly good, full recovery seems
rare [22]. The prognosis for children and adolescents
seems to be better than for adults [23,24]. Due to the long
duration of the disorder, our study estimating incidence
rates is not directly comparable with previous prevalence
surveys. However, the large sex difference reported here is
in line with results from previous reports [1,8]. The previ-
ous prevalence studies are small with respect to the num-
ber of cases, and the scarce data available have usually
limited analyses of sex and age distributions. For instance,
from the UK, an overall prevalence of 0.30% for women
and 0.09% for men and an estimated minimum yearly
incidence at 15/100,000 has been reported [14]. This study
was based on direct questioning of general practitioners
combined with electronic database searches that covered
143,000 individuals 18- to 64-years old and included data
from 122 cases only. Even stronger sex differences were
reported from a US study based on medical record review
following electronic searches in databases [15]. This latter
study covered both primary and specialist health care and
reported a prevalence of 0.12% for women and 0.02% for
men, based on data from only 76 identified cases in total.
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studies. In a telephone random-digit sampling study from
the US, 43 cases were found among 56,146 participants
[17]. The weighted prevalence estimates in that study were
0.37% for women and 0.08% for men. The study also
reports the age distribution, but not for women and men
separately. In a survey from Japan carried out among
1,430 participants in a health check-up program [11], the
prevalence was estimated at 1.0%, based on 8 male and 6
female cases.
Although results from some questionnaire studies
related to fatigue in general have been published from
Denmark [25], Iceland [13] and Norway [26], only the
Icelandic study attempts to report the prevalence of
CFS/ME. In the study from Iceland, the sex distribution
was similar to that in the current study, but the preva-
lence was higher (3.0% for women and 1.1% for men),
based on a total of only 54 cases. In the Danish study,
women had higher fatigue scores than men in a sample
of 1,082 individuals responding to a questionnaire, and
the variation in scores was also higher among women
than among men, but CFS/ME cases were not defined
[25]. The previous Norwegian study showed that the
prevalence of general fatigue was high, with a slightly
higher proportion of women than men with high scores
on a fatigue questionnaire in a random population
sample (N = 2,323) [26].
We observed a distinct age pattern in the incidence
rate of CFS/ME, with the number of cases peaking in
the age groups 10 to 19 years and 30 to 39 years. This
pattern may suggest that development of CFS/ME might
be caused by different etiological factors in different age
groups, but could also be explained by increased vulner-
ability in these age groups. The female preponderance of
CFS/ME indicates that sex hormones may play a part in
the development of the condition. Puberty and the years
after puberty are well-known vulnerable periods for the
debut of several diseases, including autoimmune and
psychiatric disorders [27]. Even though most women have
not yet reached menopause in their late thirties, many
women have given birth by this age. In pregnancy and
postpartum periods, the risk of a wide range of conditions
is increased due to rapid hormonal changes. For ins-
tance, migraine is a predominantly female disorder [28].
Menarche, menstruation, childbirth and menopause influ-
ence the frequency of migraine, and sex steroids are
considered to play an important role [29]. Migraine is also
highly prevalent in patients with CFS/ME [30]. Sex ste-
roids cross the blood–brain barrier by passive diffusion
and are also produced within the central nervous system
[31]. These neurosteroids modulate brain networks and
alter brain excitability [32]. Estrogen and progesterone are
known to influence a range of neurotransmitters inclu-
ding serotonin, norepinephrine, dopamine and endorphins.Estrogen facilitates the glutamatergic system, potentially
enhancing neuronal excitability, whereas progesterone acti-
vates GABAergic tone and suppresses neuronal reactivity.
Changes in neurotransmitter systems can affect, for ex-
ample, pain-processing networks, modulation of sensory
input and cognition. Such mechanisms have been sug-
gested to play a role in fibromyalgia [33] and may possibly
also come into play in the development of CFS/ME.
Far more women than men are affected by multiple
sclerosis (MS), and it has been suggested that the strong
phenomenological, neurobehavioral and neuroimmune
similarities between MS and CFS/ME indicate that CFS/
ME is a neuroimmune disorder [34].
From the current results, one might hypothesize that
hormonal changes increase the risk of CFS/ME in women.
The pattern may also be compatible with the hypothesis
of an infectious trigger for the condition. The age distribu-
tion observed in our study may be explained by primary
exposure to an infectious agent in adolescents (first age
peak) and subsequent reactivation of latent infection
(second age peak). It has been shown that reactivation
of latent (viral) infections may be triggered by stress-
ful events, chronic stress or pregnancy [35].
Conclusions
In summary, in this large national study, we found that
the CFS/ME risk is strongly dependent on sex and age.
The distinctive sex and age patterns might be helpful
when exploring potential causal mechanisms. Also, our
findings indicate that clinicians should have a heightened
awareness of the possibility of CFS/ME, especially in
women in certain age groups presenting with symptoms
of fatigue.
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